Yunnan Baiyao
Yunnan Baiyao Group manufactures and sells traditional Chinese medicine and preparations, personal care products, and native herbs.
Yunnan Baiyao, founded in November, 1993 and headquartered in Kunming, is a pharmaceutical and health enterprise. The founder is Chen Fashu. Listed on the SZSE on December 15, 1993, the company's major shareholders are Yunnan State-owned Assets Supervision and Administration Commission, Xinhuadu Industrial Group Co., Ltd., Jiangsu Yuyue Technology Development Co., Ltd.. Rivals that have direct and indirect competition with Yunnan Baiyao include Harbin Pharmaceutical, Tongrentang, Glaxo Smith Kline, Pfizer, etc.
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Real Estate, Consumer Discretionary, Consumer StaplesTech for Global, Globalization Footprints of the Established and the New
Research
Real Estate, Consumer Discretionary, Consumer StaplesLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Sinopharm new coronavirus vaccine approved
Another protein component special medical food was approved, and the total number of approved products increased to 57
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:30 PM
Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:00 PM
Improving service quality and enabling industrial innovation!
Pfizer submitted to FDA for authorization of emergency use of new crown vaccine
The new crown vaccine developed by academician Chen Wei and kangxinuo biology can be stable for a long time from 2 to 8 degrees
Geli pharmaceutical: asc40 (tvb-2640) China has completed phase II NASH patients